Anxa1 (annexin A1) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Anxa1 (annexin A1) Rattus norvegicus
Analyze
Symbol: Anxa1
Name: annexin A1
RGD ID: 2118
Description: Enables several functions, including DNA/DNA annealing activity; double-stranded DNA helicase activity; and phospholipase A2 inhibitor activity. Contributes to single-stranded DNA binding activity and single-stranded RNA binding activity. Involved in several processes, including estrous cycle; hepatocyte differentiation; and peptide hormone secretion. Located in extracellular space; mast cell granule; and mitochondrial membrane. Part of protein-containing complex. Is active in synaptic membrane. Used to study acute kidney failure; brain ischemia; pleurisy; and uveitis. Biomarker of several diseases, including carcinoma (multiple); cerebral infarction; eye disease (multiple); hyperthyroidism; and pulmonary fibrosis. Human ortholog(s) of this gene implicated in brain ischemia and pancreatic cancer. Orthologous to human ANXA1 (annexin A1); PARTICIPATES IN cyclooxygenase mediated pathway of arachidonic acid metabolism; INTERACTS WITH (S)-nicotine; 1-naphthyl isothiocyanate; 17alpha-ethynylestradiol.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: annexin 1; Annexin 1 (p35) (Lipocortin 1); annexin I; annexin-1; Anx1; calpactin II; calpactin-2; chromobindin-9; lipocortin 1; lipocortin I; p35; phospholipase A2 inhibitory protein
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81227,287,713 - 227,306,739 (-)NCBIGRCr8
mRatBN7.21217,861,175 - 217,877,205 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1217,861,175 - 217,877,343 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1226,201,607 - 226,217,642 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01233,138,171 - 233,154,203 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01225,956,194 - 225,972,229 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01237,893,983 - 237,910,002 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1237,893,966 - 237,910,012 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01245,192,875 - 245,220,057 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41223,478,436 - 223,494,455 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11223,642,460 - 223,658,478 (-)NCBI
Celera1215,138,950 - 215,154,969 (-)NCBICelera
Cytogenetic Map1q51NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (IDA)
Animal Mammary Neoplasms  (ISO)
asthma  (ISO)
autistic disorder  (ISO)
Blister  (ISO)
brain ischemia  (IMP,ISO)
Breast Neoplasms  (ISO)
carcinoma  (ISO)
cataract  (IEP,ISO)
Cerebral Hemorrhage  (IEP)
cerebral infarction  (IEP)
colitis  (IEP)
contact dermatitis  (ISO)
COVID-19  (ISO)
Craniofacial Abnormalities  (ISO)
Delayed Hypersensitivity  (ISO)
Discoid Lupus Erythematosus  (ISO)
dry eye syndrome  (ISO)
ductal carcinoma in situ  (ISO)
encephalitis  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Arthritis  (IMP,ISO)
Experimental Autoimmune Encephalomyelitis  (IEP)
Experimental Autoimmune Neuritis  (IEP)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (IEP,ISO)
Experimental Mammary Neoplasms  (IEP,ISO)
genetic disease  (ISO)
Hyperalgesia  (IEP,IMP)
hypertension  (IEP,ISO)
hyperthyroidism  (IEP)
hypothyroidism  (IEP)
Inflammation  (IEP)
invasive ductal carcinoma  (ISO)
ischemia  (IEP)
keratosis follicularis  (ISO)
kidney disease  (ISO)
Kidney Reperfusion Injury  (IDA)
lung adenocarcinoma  (ISO)
Lymphatic Metastasis  (ISO)
malignant astrocytoma  (ISO)
Mouth Neoplasms  (ISO)
Myocardial Reperfusion Injury  (IEP,ISO)
Nasal Polyps  (ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (IEP,IMP,ISO)
Ocular Toxoplasmosis  (ISO)
pancreatic cancer  (ISO)
paranasal sinus benign neoplasm  (ISO)
pleurisy  (IDA)
Prostatic Neoplasms  (ISO)
psoriasis  (ISO)
pulmonary fibrosis  (IEP)
renal cell carcinoma  (IEP)
Rhinosinusitis  (ISO)
seborrheic keratosis  (ISO)
Skin Neoplasms  (ISO)
Spinal Cord Injuries  (IEP,ISO)
squamous cell carcinoma  (ISO)
stomach cancer  (IEP)
stomach disease  (ISO)
transitional cell carcinoma  (IEP)
uveitis  (IDA,IEP,ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-lariciresinol  (ISO)
(-)-alpha-phellandrene  (ISO)
(-)-demecolcine  (ISO)
(-)-lariciresinol  (ISO)
(R)-noradrenaline  (ISO)
(S)-nicotine  (EXP)
1,1-dichloroethene  (ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1,4-phenylenediamine  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
1-naphthyl isothiocyanate  (EXP)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3-dimethoxynaphthalene-1,4-dione  (ISO)
2,4,6-trinitrobenzenesulfonic acid  (ISO)
2-hydroxypropanoic acid  (ISO)
3-chloropropane-1,2-diol  (EXP)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (EXP)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (EXP)
9-cis-retinoic acid  (ISO)
acrolein  (ISO)
aflatoxin B1  (EXP,ISO)
all-trans-4-oxoretinoic acid  (ISO)
all-trans-retinoic acid  (EXP,ISO)
alpha-phellandrene  (ISO)
alpha-pinene  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
amphetamine  (EXP)
aniline  (EXP)
anthracen-2-amine  (EXP)
aristolochic acid A  (ISO)
Aroclor 1254  (ISO)
arotinoid acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (EXP)
arsenous acid  (ISO)
ATP  (EXP)
Bardoxolone methyl  (ISO)
benzatropine  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
beta-naphthoflavone  (EXP)
bilirubin IXalpha  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisphenol A  (EXP,ISO)
Bisphenol B  (ISO)
bisphenol F  (ISO)
cadmium atom  (EXP,ISO)
cadmium dichloride  (ISO)
cadmium sulfate  (ISO)
calcium atom  (EXP)
calcium(0)  (EXP)
carbamazepine  (ISO)
carbon nanotube  (ISO)
carbonyl sulfide  (EXP)
carrageenan  (ISO)
CHIR 99021  (ISO)
chloropicrin  (ISO)
choline  (ISO)
chromium(6+)  (EXP)
Cinobufagin  (ISO)
cisplatin  (ISO)
clozapine  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
copper(II) sulfate  (ISO)
cortisol  (ISO)
crocidolite asbestos  (ISO)
Cuprizon  (EXP,ISO)
cyclosporin A  (ISO)
D-penicillamine  (EXP)
DDT  (EXP)
Deoxycorticosterone acetate  (EXP)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
diazinon  (EXP)
dibutyl phthalate  (EXP,ISO)
dieldrin  (EXP)
diethyl maleate  (ISO)
diethyldithiocarbamic acid  (EXP)
dimethylarsinous acid  (ISO)
dioxygen  (ISO)
disodium selenite  (ISO)
diuron  (EXP,ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
endosulfan  (EXP)
entinostat  (ISO)
ethanol  (EXP,ISO)
ethyl methanesulfonate  (ISO)
eurycomanone  (ISO)
fluoxetine  (EXP)
flurbiprofen  (ISO)
fluticasone  (ISO)
folic acid  (ISO)
formaldehyde  (ISO)
furan  (EXP)
genistein  (EXP,ISO)
gentamycin  (EXP)
glycidyl methacrylate  (ISO)
glyphosate  (EXP,ISO)
graphite  (ISO)
hexachlorobenzene  (EXP)
hyaluronic acid  (EXP)
hydrogen peroxide  (EXP)
hydroquinone  (ISO)
ibuprofen  (ISO)
inulin  (ISO)
iron atom  (EXP)
iron dichloride  (ISO)
iron(0)  (EXP)
isoflavones  (EXP)
isoprenaline  (ISO)
ivermectin  (ISO)
ketoconazole  (EXP)
kojic acid  (ISO)
L-ascorbic acid  (EXP,ISO)
L-ascorbic acid 2-phosphate  (ISO)
L-methionine  (ISO)
lasalocid  (ISO)
lead diacetate  (EXP)
lead(0)  (EXP)
lead(II) chloride  (ISO)
levofloxacin  (EXP)
lipopolysaccharide  (EXP,ISO)
lithocholic acid  (ISO)
magnesium atom  (EXP)
mercury dibromide  (ISO)
metacetamol  (ISO)
methimazole  (EXP)
methoxychlor  (EXP)
methyl methanesulfonate  (ISO)
methylmercury chloride  (ISO)
methylparaben  (ISO)
miconazole  (EXP)
mifepristone  (ISO)
monosodium L-glutamate  (ISO)
N-methyl-4-phenylpyridinium  (EXP)
N-nitrosodiethylamine  (EXP)
N-nitrosodimethylamine  (EXP)
nickel sulfate  (ISO)
nicotine  (EXP)
ochratoxin A  (EXP)
ouabain  (ISO)
oxaliplatin  (EXP)
ozone  (ISO)
p-chloromercuribenzoic acid  (ISO)
paclitaxel  (ISO)
panobinostat  (ISO)
paracetamol  (ISO)
paraquat  (EXP)
perfluorohexanesulfonic acid  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (EXP)
phenobarbital  (EXP,ISO)
phenylmercury acetate  (ISO)
PhIP  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
phosgene  (ISO)
potassium chloride  (EXP)
potassium dichromate  (EXP)
Propiverine  (EXP)
prostaglandin E2  (ISO)
quercetin  (EXP,ISO)
quinoline  (ISO)
rac-lactic acid  (ISO)
resveratrol  (ISO)
rimonabant  (ISO)
rofecoxib  (ISO)
rotenone  (EXP)
SB 431542  (ISO)
senecionine  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (ISO)
sodium arsenite  (EXP,ISO)
sodium fluoride  (ISO)
sulfadimethoxine  (EXP)
sulforaphane  (ISO)
sunitinib  (ISO)
T-2 toxin  (ISO)
tacrolimus hydrate  (EXP)
tanespimycin  (ISO)
tetrachloromethane  (ISO)
thapsigargin  (EXP)
thioacetamide  (EXP)
thiophenes  (ISO)
titanium dioxide  (ISO)
torcetrapib  (ISO)
triadimefon  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triphenyl phosphate  (EXP)
troglitazone  (ISO)
tungsten  (ISO)
tunicamycin  (ISO)
valproic acid  (ISO)
vancomycin  (ISO)
vinclozolin  (EXP)
vincristine  (ISO)
XAV939  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
actin cytoskeleton organization  (IEA,ISO,ISS)
adaptive immune response  (IEA)
alpha-beta T cell differentiation  (IEA,ISO)
arachidonic acid secretion  (IEA,ISO)
cell surface receptor signaling pathway  (IDA,IEA)
cellular response to glucocorticoid stimulus  (IBA,IDA,IEA,ISO)
cellular response to hydrogen peroxide  (IEA,IMP)
cellular response to vascular endothelial growth factor stimulus  (IEA,ISO)
DNA duplex unwinding  (IDA,IEA)
endocrine pancreas development  (IEA,IEP)
estrous cycle  (IEA,IEP)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger  (IEA,ISO,ISS)
gliogenesis  (IEA,IEP)
granulocyte chemotaxis  (IEA,ISO,ISS)
hepatocyte differentiation  (IEA,IEP)
inflammatory response  (IEA,ISO,ISS)
innate immune response  (IEA)
insulin secretion  (IDA,IEA)
keratinocyte differentiation  (IEA,ISO)
monocyte chemotaxis  (IEA,ISO,ISS)
myoblast migration involved in skeletal muscle regeneration  (IEA,ISO)
negative regulation of exocytosis  (IEA,ISO,ISS)
negative regulation of interleukin-8 production  (IEA,ISO)
negative regulation of phospholipase A2 activity  (IDA)
negative regulation of protein secretion  (IMP)
negative regulation of T-helper 2 cell differentiation  (IEA,ISO,ISS)
neutrophil activation  (IEA,ISO,ISS)
neutrophil clearance  (IEA,ISO)
neutrophil homeostasis  (ISO)
phagocytosis  (IBA,ISO,ISS)
positive regulation of apoptotic process  (IMP)
positive regulation of cell migration involved in sprouting angiogenesis  (IEA,ISO)
positive regulation of G1/S transition of mitotic cell cycle  (IEA,ISO)
positive regulation of interleukin-2 production  (IEA,ISO,ISS)
positive regulation of neutrophil apoptotic process  (IEA,ISO)
positive regulation of prostaglandin biosynthetic process  (IEA,IMP)
positive regulation of T cell proliferation  (IEA,ISO,ISS)
positive regulation of T-helper 1 cell differentiation  (IEA,ISO,ISS)
positive regulation of vesicle fusion  (IEA,ISO)
positive regulation of wound healing  (IEA,ISO,ISS)
prolactin secretion  (IEA,IMP)
prostate gland development  (IEA,IEP)
regulation of cell population proliferation  (ISO)
regulation of cell shape  (IEA,ISO,ISS)
regulation of hormone secretion  (IEA,ISO,ISS)
regulation of inflammatory response  (IEA,ISO,ISS)
regulation of interleukin-1 production  (IEA,ISO,ISS)
regulation of leukocyte migration  (IEA,ISO,ISS)
response to estradiol  (IEA,IEP)
response to glucocorticoid  (IEP)
response to hormone  (IEP)
response to interleukin-1  (IEA,IEP)
response to organic cyclic compound  (IEP)
response to peptide hormone  (IEA,IEP)
response to X-ray  (IEA,IEP)
response to xenobiotic stimulus  (IEP)
signal transduction  (IBA,ISO)

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Annexin A1 protein attenuates cyclosporine-induced renal hemodynamics changes and macrophage infiltration in rats. Araujo LP, etal., Inflamm Res. 2012 Mar;61(3):189-96. doi: 10.1007/s00011-011-0400-z. Epub 2011 Nov 19.
2. A novel effect for annexin 1-derived peptide ac2-26: reduction of allergic inflammation in the rat. Bandeira-Melo C, etal., J Pharmacol Exp Ther. 2005 Jun;313(3):1416-22. Epub 2005 Mar 22.
3. Loss of annexin A1 expression in breast cancer progression. Cao Y, etal., Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):530-4. doi: 10.1097/PAI.0b013e31817432c3.
4. Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Chuthapisith S, etal., Eur J Cancer. 2009 May;45(7):1274-81. doi: 10.1016/j.ejca.2008.12.026. Epub 2009 Jan 24.
5. Inflammatory neutrophils secrete annexin 1 during experimentally induced colitis in rats. Comera C, etal., Dig Dis Sci. 1999 Jul;44(7):1448-57.
6. Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer. Cui L, etal., Proteomics. 2007 Nov;7(22):4192-202.
7. Mast cells modulate the inflammatory process in endotoxin-induced uveitis. da Silva PS, etal., Mol Vis. 2011;17:1310-9. Epub 2011 May 8.
8. Changes in proteomic profiles in different prostate lobes of male rats throughout growth and development and aging stages of the life span. Das A, etal., Prostate. 2013 Mar;73(4):363-75. doi: 10.1002/pros.22576. Epub 2012 Aug 21.
9. The influence of 17beta-estradiol on annexin 1 expression in the anterior pituitary of the female rat and in a folliculo-stellate cell line. Davies E, etal., J Endocrinol. 2007 Feb;192(2):429-42.
10. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. de Graauw M, etal., Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6340-5. doi: 10.1073/pnas.0913360107. Epub 2010 Mar 22.
11. Annexin expressions are temporally and spatially regulated during rat hepatocyte differentiation. Della Gaspera B, etal., Dev Dyn. 2001 Oct;222(2):206-17.
12. In vivo modulation of annexins I, II and V expression by thyroxine and methylthiouracil. el Btaouri H, etal., Eur J Biochem. 1996 Dec 15;242(3):506-11.
13. Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. Facio FN Jr, etal., J Mol Med (Berl). 2011 Jan;89(1):51-63. doi: 10.1007/s00109-010-0684-4. Epub 2010 Oct 16.
14. Expression of genes that encode the annexin-1 and galectin-1 proteins in nasal polyposis and their modulation by glucocorticoid. Fernandes AM, etal., Braz J Otorhinolaryngol. 2010 Mar-Apr;76(2):213-8.
15. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Ferreira SH, etal., Br J Pharmacol. 1997 Jul;121(5):883-8.
16. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
17. Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system. Gavins FN, etal., FASEB J. 2012 Dec;26(12):4977-89. doi: 10.1096/fj.12-205971. Epub 2012 Sep 10.
18. Actin and annexins I and II are among the main endothelial plasmalemma-associated proteins forming early glucose adducts in experimental diabetes. Ghitescu LD, etal., Diabetes. 2001 Jul;50(7):1666-74.
19. Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro. Girol AP, etal., J Immunol. 2013 Jun 1;190(11):5689-701. doi: 10.4049/jimmunol.1202030. Epub 2013 May 3.
20. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
21. Increased lipocortin-1 (annexin-1) expression in the sciatic nerve of Lewis rats with experimental autoimmune neuritis. Gold R, etal., Acta Neuropathol. 1999 Dec;98(6):583-9.
22. Arachidonic acid metabolism in cells transfected with sense and anti-sense cDNA to annexin I. Hayashi J, etal., Biochem Mol Biol Int. 1993 Sep;31(1):143-51.
23. Lipocortin (Annexin) I heterotetramer binds to purine RNA and pyrimidine DNA. Hirata A and Hirata F, Biochem Biophys Res Commun. 1999 Nov;265(1):200-4.
24. Carcinogenic heavy metals replace Ca2+ for DNA binding and annealing activities of mono-ubiquitinated annexin A1 homodimer. Hirata A, etal., Toxicol Appl Pharmacol. 2010 Oct 1;248(1):45-51. doi: 10.1016/j.taap.2010.07.005. Epub 2010 Jul 22.
25. Identification of proteins that modify cataract of mouse eye lens. Hoehenwarter W, etal., Proteomics. 2008 Dec;8(23-24):5011-24. doi: 10.1002/pmic.200800380.
26. Effect of annexin I on insulin secretion through surface binding sites in rat pancreatic islets. Hong SH, etal., FEBS Lett 2002 Dec 4;532(1-2):17-20.
27. Membrane-induced folding and structure of membrane-bound annexin A1 N-terminal peptides: implications for annexin-induced membrane aggregation. Hu NJ, etal., Biophys J. 2008 Mar 1;94(5):1773-81. Epub 2007 Nov 9.
28. Effect of annexin-1 on experimental autoimmune encephalomyelitis (EAE) in the rat. Huitinga I, etal., Clin Exp Immunol. 1998 Jan;111(1):198-204.
29. Prolonged gaseous hypothermia prevents the upregulation of phagocytosis-specific protein annexin 1 and causes low-amplitude EEG activity in the aged rat brain after cerebral ischemia. Joseph C, etal., J Cereb Blood Flow Metab. 2012 Aug;32(8):1632-42. doi: 10.1038/jcbfm.2012.65. Epub 2012 May 23.
30. Global gene expression profiling of ischemic preconditioning in the rat retina. Kamphuis W, etal., Mol Vis. 2007 Jun 28;13:1020-30.
31. Involvement of lipocortin I in development of galactose-induced cataracts in rat. Koshimoto HN, etal., Exp Eye Res. 1992 May;54(5):817-20.
32. Correlation of gene and protein structure of rat and human lipocortin I. Kovacic RT, etal., Biochemistry 1991 Sep 17;30(37):9015-21.
33. Anti-annexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus. Kretz CC, etal., Exp Dermatol. 2010 Oct;19(10):919-21. doi: 10.1111/j.1600-0625.2010.01145.x.
34. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. La M, etal., FASEB J. 2001 Oct;15(12):2247-56.
35. Upregulation of annexins I, II, and V after traumatic spinal cord injury in adult rats. Liu N, etal., J Neurosci Res. 2004 Aug 1;77(3):391-401.
36. Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury. Liu NK, etal., J Neuropathol Exp Neurol. 2007 Oct;66(10):932-43.
37. [In vivo effect of annexin I down-regulation on the growth of human pancreatic cancer in nude mice] Liu Q, etal., Zhonghua Zhong Liu Za Zhi. 2008 Dec;30(12):897-900.
38. Brain genomics of intracerebral hemorrhage. Lu A, etal., J Cereb Blood Flow Metab. 2006 Feb;26(2):230-52.
39. Annexin A1 attenuates EMT and metastatic potential in breast cancer. Maschler S, etal., EMBO Mol Med. 2010 Oct;2(10):401-14. doi: 10.1002/emmm.201000095.
40. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
41. The involvement of anti-inflammatory protein, annexin A1, in ocular toxoplasmosis. Mimura KK, etal., Mol Vis. 2012;18:1583-93. Epub 2012 Jun 15.
42. Interleukin-1beta induces the expression of lipocortin 1 mRNA in cultured rat cortical astrocytes. Miyachi T, etal., Neurosci Res. 2001 May;40(1):53-60.
43. Up-regulation of lipocortin-1 and its mRNA in reactive astrocytes in kainate-lesioned rat cerebellum. Mullens L, etal., J Neuroimmunol. 1994 Feb;50(1):25-33.
44. Annexin-1-deficient mice exhibit spontaneous airway hyperresponsiveness and exacerbated allergen-specific antibody responses in a mouse model of asthma. Ng FS, etal., Clin Exp Allergy. 2011 Dec;41(12):1793-803. doi: 10.1111/j.1365-2222.2011.03855.x. Epub 2011 Sep 20.
45. Molecules in focus: cytosolic phospholipase A2-alpha. Niknami M, etal., Int J Biochem Cell Biol. 2009 May;41(5):994-7. doi: 10.1016/j.biocel.2008.07.017. Epub 2008 Aug 8.
46. Changes in annexin I and II levels during the postnatal development of rat pancreatic islets. Ohnishi M, etal., J Cell Sci. 1994 Aug;107 ( Pt 8):2117-25.
47. Cell localization of the anti-inflammatory protein annexin 1 during experimental inflammatory response. Oliani SM and Perretti M, Ital J Anat Embryol 2001;106(2 Suppl 1):69-77.
48. An immunocytochemical and in situ hybridization analysis of annexin 1 expression in rat mast cells: modulation by inflammation and dexamethasone. Oliani SM, etal., Lab Invest. 2000 Sep;80(9):1429-38.
49. Annexin 1 localisation in tissue eosinophils as detected by electron microscopy. Oliani SM, etal., Mediators Inflamm. 2002 Oct;11(5):287-92.
50. Changes in gene expression during chemical-induced nephrocarcinogenicity in the Eker rat. Patel SK, etal., Mol Carcinog. 2003 Nov;38(3):141-54.
51. Annexin 1 exerts anti-nociceptive effects after peripheral inflammatory pain through formyl-peptide-receptor-like 1 in rat dorsal root ganglion. Pei L, etal., Br J Anaesth. 2011 Dec;107(6):948-58. doi: 10.1093/bja/aer299. Epub 2011 Oct 11.
52. Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Pencil SD and Toth M, Clin Exp Metastasis. 1998 Feb;16(2):113-21.
53. Modulation of cellular annexin I in human leukocytes infiltrating DTH skin reactions. Perretti M, etal., J Leukoc Biol. 1999 May;65(5):583-9.
54. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Perretti M, etal., Nat Med 2002 Nov;8(11):1296-302.
55. Myenteric denervation in gastric carcinogenesis: differential modulation of nitric oxide and annexin-A1. Polli-Lopes AC, etal., Int J Clin Exp Pathol. 2013;6(1):13-23. Epub 2012 Nov 20.
56. Annexin 1 is present in different molecular forms in rat cerebral cortex. Pradel LA and Rendon A, FEBS Lett. 1993 Jul 19;327(1):41-4.
57. Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26). Qin C, etal., Br J Pharmacol. 2013 Jan;168(1):238-52. doi: 10.1111/j.1476-5381.2012.02176.x.
58. Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain. Relton JK, etal., J Exp Med. 1991 Aug 1;174(2):305-10.
59. GOA pipeline RGD automated data pipeline
60. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
61. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
62. Down-regulation of annexin A1 and A2 protein expression in intestinal-type sinonasal adenocarcinomas. Rodrigo JP, etal., Hum Pathol. 2011 Jan;42(1):88-94. doi: 10.1016/j.humpath.2010.05.017. Epub 2010 Oct 20.
63. Modulation of cell death pathways to apoptosis and necrosis of H2O2-treated rat thymocytes by lipocortin I. Sakamoto T, etal., Biochem Biophys Res Commun. 1996 Mar 27;220(3):643-7.
64. Growth hormone induces tyrosine phosphorylation of annexin I in rat osteosarcoma cells. Salles JP, etal., Endocrinology. 1996 Oct;137(10):4358-62.
65. Localization of annexin I (lipocortin I, p35) mRNA in normal and diseased human skin by in situ hybridization. Sato-Matsumura KC, etal., Arch Dermatol Res. 1996 Sep;288(10):565-9.
66. Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. Shan L, etal., Toxicol Pathol. 2005;33(7):768-75.
67. Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. Shen J, etal., Carcinogenesis. 2012 Nov;33(11):2208-19. doi: 10.1093/carcin/bgs213. Epub 2012 Jul 10.
68. Molecular cloning and expression in Escherichia coli of the cDNA coding for rat lipocortin I (calpactin II). Shimizu Y, etal., Gene. 1988 May 15;65(1):141-7.
69. Hypothesis: familial Mediterranean fever--a genetic disorder of the lipocortin family? Shohat M, etal., Am J Med Genet 1989 Oct;34(2):163-7.
70. Tear proteome and protein network analyses reveal a novel pentamarker panel for tear film characterization in dry eye and meibomian gland dysfunction. Soria J, etal., J Proteomics. 2013 Jan 14;78:94-112. doi: 10.1016/j.jprot.2012.11.017. Epub 2012 Nov 29.
71. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
72. Annexin 1 (lipocortin 1) mediates the glucocorticoid inhibition of cyclic adenosine 3',5'-monophosphate-stimulated prolactin secretion. Taylor AD, etal., Endocrinology. 2000 Jun;141(6):2209-19.
73. Dexamethasone suppresses the release of prolactin from the rat anterior pituitary gland by lipocortin 1 dependent and independent mechanisms. Taylor AD, etal., Neuroendocrinology. 1995 Nov;62(5):530-42.
74. Differential regulation of transient receptor potential melastatin 6 and 7 cation channels by ANG II in vascular smooth muscle cells from spontaneously hypertensive rats. Touyz RM, etal., Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R73-8. Epub 2005 Aug 18.
75. Annexin I in fibrotic rat lung and cultured lung fibroblasts following irradiation. Ts'ao C, etal., Int J Radiat Biol. 1997 Aug;72(2):227-34.
76. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Tyburczy ME, etal., Am J Pathol. 2010 Apr;176(4):1878-90. doi: 10.2353/ajpath.2010.090950. Epub 2010 Feb 4.
77. Chronic rhinosinusitis with nasal polyps: a proteomic analysis. Upton DC, etal., Ann Otol Rhinol Laryngol. 2011 Dec;120(12):780-6.
78. Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. Vishwanath BS, etal., J Clin Invest. 1996 Jul 15;98(2):365-71.
79. Expression of annexin and annexin-mRNA in rat brain under influence of steroid drugs. Voermans PH, etal., Acta Neurochir Suppl. 1997;70:222-4.
80. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Wallner BP, etal., Nature. 1986 Mar 6-12;320(6057):77-81.
81. Annexin A1 expression and its prognostic significance in human breast cancer. Wang LP, etal., Neoplasma. 2010;57(3):253-9.
82. Zhonghua zhong liu za zhi [Chinese journal of oncology] Xue LY, etal., Zhonghua Zhong Liu Za Zhi. 2007 Jun;29(6):444-8.
83. Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Yang Y, etal., Arthritis Rheum. 1999 Jul;42(7):1538-44.
84. Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation. Yang YH, etal., J Immunol. 2013 Feb 1;190(3):997-1007. doi: 10.4049/jimmunol.1202236. Epub 2012 Dec 24.
85. Clinical significance of annexin A1 expression in breast cancer. Yom CK, etal., J Breast Cancer. 2011 Dec;14(4):262-8. doi: 10.4048/jbc.2011.14.4.262. Epub 2011 Dec 27.
86. Purification, identification and phosphorylation of annexin I from rat liver mitochondria. Yoshii K, etal., Acta Med Okayama. 2000 Apr;54(2):57-65.
87. Gliogenesis in postnatal rat optic nerve: LC1 + microglia and S100-beta + astrocytes. Zhang MZ and McKanna JA, Brain Res Dev Brain Res. 1997 Jul 18;101(1-2):27-36.
88. Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. Zhang YG, etal., J Hypertens. 2008 Jun;26(6):1119-26.
Additional References at PubMed
PMID:2138016   PMID:2958780   PMID:3013422   PMID:8885232   PMID:10908733   PMID:12475898   PMID:12553880   PMID:12586783   PMID:12595246   PMID:14506282   PMID:14516791   PMID:15187149  
PMID:15226301   PMID:15489334   PMID:17008549   PMID:17218541   PMID:17384087   PMID:18504258   PMID:18767904   PMID:18802107   PMID:19056867   PMID:19095957   PMID:19182904   PMID:19190083  
PMID:19199708   PMID:19625660   PMID:20139728   PMID:21362503   PMID:21423176   PMID:21745559   PMID:21957127   PMID:22056994   PMID:22164217   PMID:22206666   PMID:22664934   PMID:22773844  
PMID:22791338   PMID:23106098   PMID:23144744   PMID:23376485   PMID:23533145   PMID:23580065   PMID:23587191   PMID:24254883   PMID:24939696   PMID:25468996   PMID:25616869   PMID:25664854  
PMID:26063293   PMID:26609771   PMID:26616057   PMID:27584794   PMID:27782092   PMID:28259758   PMID:29213013   PMID:29867124   PMID:30272262   PMID:31148248   PMID:32856352   PMID:33796096  
PMID:34951334   PMID:35896374   PMID:36269280   PMID:36279933  


Genomics

Comparative Map Data
Anxa1
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81227,287,713 - 227,306,739 (-)NCBIGRCr8
mRatBN7.21217,861,175 - 217,877,205 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1217,861,175 - 217,877,343 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1226,201,607 - 226,217,642 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01233,138,171 - 233,154,203 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01225,956,194 - 225,972,229 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01237,893,983 - 237,910,002 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1237,893,966 - 237,910,012 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01245,192,875 - 245,220,057 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41223,478,436 - 223,494,455 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11223,642,460 - 223,658,478 (-)NCBI
Celera1215,138,950 - 215,154,969 (-)NCBICelera
Cytogenetic Map1q51NCBI
ANXA1
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38973,151,865 - 73,170,393 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl973,151,865 - 73,170,393 (+)EnsemblGRCh38hg38GRCh38
GRCh37975,766,781 - 75,785,309 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 36974,956,601 - 74,975,127 (+)NCBINCBI36Build 36hg18NCBI36
Build 34972,996,334 - 73,014,861NCBI
Celera946,339,417 - 46,357,944 (+)NCBICelera
Cytogenetic Map9q21.13ENTREZGENE
HuRef945,589,147 - 45,607,684 (+)NCBIHuRef
CHM1_1975,913,630 - 75,932,174 (+)NCBICHM1_1
T2T-CHM13v2.0985,303,301 - 85,321,829 (+)NCBIT2T-CHM13v2.0
Anxa1
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391920,350,798 - 20,368,035 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1920,350,792 - 20,368,308 (-)EnsemblGRCm39 Ensembl
GRCm381920,373,434 - 20,390,671 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1920,373,428 - 20,390,944 (-)EnsemblGRCm38mm10GRCm38
MGSCv371920,447,924 - 20,465,161 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361920,440,455 - 20,457,696 (-)NCBIMGSCv36mm8
Celera1921,098,423 - 21,115,607 (-)NCBICelera
Cytogenetic Map19BNCBI
cM Map1913.83NCBI
Anxa1
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0NW_0049555125,686,508 - 5,703,645 (-)NCBIChiLan1.0ChiLan1.0
ANXA1
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v21172,336,793 - 72,355,498 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan1972,342,859 - 72,361,441 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0951,647,404 - 51,665,990 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1971,930,148 - 71,948,779 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl971,929,728 - 71,948,779 (+)Ensemblpanpan1.1panPan2
ANXA1
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1184,744,159 - 84,763,011 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl184,744,163 - 84,763,011 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha185,210,169 - 85,229,021 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0185,194,249 - 85,213,101 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl185,194,253 - 85,213,101 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1184,963,509 - 84,982,291 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0184,666,120 - 84,684,901 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0185,425,388 - 85,444,242 (-)NCBIUU_Cfam_GSD_1.0
Anxa1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404947132,030,632 - 132,048,702 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365039,124,264 - 9,142,413 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049365039,124,314 - 9,142,372 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
ANXA1
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1226,414,306 - 226,432,279 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11226,414,200 - 226,431,963 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21252,989,694 - 253,007,485 (+)NCBISscrofa10.2Sscrofa10.2susScr3
ANXA1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.11284,207,818 - 84,226,438 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1284,207,820 - 84,226,562 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603872,640,484 - 72,659,219 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Anxa1
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_004624811764,940 - 782,198 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_004624811765,338 - 782,203 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Anxa1
88 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:31
Count of miRNA genes:26
Interacting mature miRNAs:30
Transcripts:ENSRNOT00000023664
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1578780Cm52Cardiac mass QTL 523.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)181591954219808434Rat
1354606Bp246Blood pressure QTL 2463.6arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)1102813953218753816Rat
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
737828Hcas3Hepatocarcinoma susceptibility QTL 34.9liver integrity trait (VT:0010547)liver tumorous lesion volume to total liver volume ratio (CMO:0001082)1144267353222987745Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
7771612Cm80Cardiac mass QTL 808.4heart left ventricle mass (VT:0007031)heart left ventricle weight (CMO:0000776)1149448574221264292Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1358886Bp260Blood pressure QTL 2603.67arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1151162766225824951Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
2312420Pur17Proteinuria QTL 177.10.0001urine protein amount (VT:0005160)urine total protein excretion rate (CMO:0000756)1156677124218753816Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
631214Bw61Body weight QTL613.40.0001intramuscular adipose amount (VT:0010044)intramuscular fat area (CMO:0001162)1173108781218108781Rat
70163Bw20Body weight QTL 205.1body mass (VT:0001259)body weight (CMO:0000012)1174133260219133260Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1600380Niddm70Non-insulin dependent diabetes mellitus QTL 703.10.0008blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1176550523221550523Rat
10059600Bp378Blood pressure QTL 3783.080.05arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1176869060221869060Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
1558658Bw59Body weight QTL 593.50.0003body mass (VT:0001259)body weight (CMO:0000012)1178784622223784622Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
6903303Scl34Serum cholesterol QTL 342.50.0033blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)1180359209218108781Rat
737977Bp160Blood pressure QTL 1600.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1181133855226133855Rat
2293083Iddm25Insulin dependent diabetes mellitus QTL 254.18blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1181829673224569684Rat
634312Bp143Blood pressure QTL 14330.0002arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1182623426219932796Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
631838Niddm36Non-insulin dependent diabetes mellitus QTL 360.01insulin secretion trait (VT:0003564)calculated pancreatic islet insulin release measurement (CMO:0001217)1184550676229550676Rat
1300145Rf7Renal function QTL 72.96urine creatinine amount (VT:0010540)urine creatinine level (CMO:0000125)1185145134221264292Rat
2312564Glom18Glomerulus QTL 182.40.003kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1185356336231689108Rat
1582206Kidm33Kidney mass QTL 336.9kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1188377360224054420Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
10059590Kidm44Kidney mass QTL 443.420.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1191033875236033875Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1358292Cm37Cardiac mass QTL 376.20.00000081heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1197670404242670404Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1197697768238755659Rat
2302375Bw83Body weight QTL 834.870.0002body mass (VT:0001259)body weight (CMO:0000012)1197697768242697768Rat
61376Bp42Blood pressure QTL 4223.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1197814409242814409Rat
1298084Thym4Thymus enlargement QTL 410.68thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)1197814409242814409Rat
1357335Bw39Body weight QTL 393.3body mass (VT:0001259)body weight (CMO:0000012)1197814409242814409Rat
1331790Bp201Blood pressure QTL 2013.127arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1198211513225126682Rat
634313Niddm43Non-insulin dependent diabetes mellitus QTL 43blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459259647894Rat
2292218Kidm35Kidney mass QTL 35kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1199368955224569684Rat
2293694Bss38Bone structure and strength QTL 387.050.0001femur strength trait (VT:0010010)femur stiffness (CMO:0001674)1201554356246554356Rat
7394701Uae46Urinary albumin excretion QTL 463.60.0056urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1201554356246554356Rat
2300175Bmd40Bone mineral density QTL 4015.40.0001femur mineral mass (VT:0010011)bone mineral density (CMO:0001226)1201554356246554356Rat
2293655Bss36Bone structure and strength QTL 3610.660.0001femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1201554356246554356Rat
2293674Bss39Bone structure and strength QTL 397.10.0001femur strength trait (VT:0010010)femur total energy absorbed before break (CMO:0001677)1201554356246554356Rat
10059587Bw173Body weight QTL 1733.230.025body mass (VT:0001259)body weight (CMO:0000012)1202069611247069611Rat
1600363Hc6Hypercalciuria QTL 62.7urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1203995416244113296Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1206081677251081677Rat
61403Niddm4Non-insulin dependent diabetes mellitus QTL 4blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1206329708222745518Rat
1357399Bw45Body weight QTL 453.05body mass (VT:0001259)body mass index (BMI) (CMO:0000105)1206329708251329708Rat
1357404Bw42Body weight QTL 424.490.0001body mass (VT:0001259)body weight (CMO:0000012)1206329708251329708Rat
1300168Bp170Blood pressure QTL 1702.76arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1207702246228581766Rat
1358916Kidm22Kidney mass QTL 223.32kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1210702053240947965Rat
1358890Bp259Blood pressure QTL 2593.06arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1210702053260522016Rat
2292216Bw80Body weight QTL 803.230.0019body mass (VT:0001259)body weight (CMO:0000012)1213533809243914901Rat
724538Kidm1Kidney mass QTL 13.2kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1213707201252085212Rat
734768Niddm59Non-insulin dependent diabetes mellitus QTL 59body mass (VT:0001259)body weight (CMO:0000012)1213843987258843987Rat
634340Hcar5Hepatocarcinoma resistance QTL 58liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1214537555226660468Rat
61455Niddm7Non-insulin dependent diabetes mellitus QTL 75.5blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1214537555238757011Rat
70211Niddm24Non-insulin dependent diabetes mellitus QTL 243.79blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1214647894259647894Rat
1549910Bw54Body weight QTL 540.05body mass (VT:0001259)body weight (CMO:0000012)1214647894259647894Rat
61327Eae7Experimental allergic encephalomyelitis QTL 75.6body mass (VT:0001259)change in body weight (CMO:0002045)1216255568260522016Rat
2302040Pia35Pristane induced arthritis QTL 353.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)1216255568260522016Rat

Markers in Region
RH127656  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21217,861,231 - 217,861,437 (+)MAPPERmRatBN7.2
Rnor_6.01237,894,040 - 237,894,245NCBIRnor6.0
Rnor_5.01245,192,932 - 245,193,137UniSTSRnor5.0
RGSC_v3.41223,478,493 - 223,478,698UniSTSRGSC3.4
Celera1215,139,007 - 215,139,212UniSTS
Cytogenetic Map1q51UniSTS
RH129631  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21217,861,215 - 217,861,400 (+)MAPPERmRatBN7.2
Rnor_6.01237,894,024 - 237,894,208NCBIRnor6.0
Rnor_5.01245,192,916 - 245,193,100UniSTSRnor5.0
RGSC_v3.41223,478,477 - 223,478,661UniSTSRGSC3.4
Celera1215,138,991 - 215,139,175UniSTS
RH 3.4 Map3555.4UniSTS
Cytogenetic Map1q51UniSTS
RH94593  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21217,861,226 - 217,861,413 (+)MAPPERmRatBN7.2
Rnor_6.01237,894,035 - 237,894,221NCBIRnor6.0
Rnor_5.01245,192,927 - 245,193,113UniSTSRnor5.0
RGSC_v3.41223,478,488 - 223,478,674UniSTSRGSC3.4
Celera1215,139,002 - 215,139,188UniSTS
Cytogenetic Map1q51UniSTS
RH143668  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21217,876,465 - 217,876,625 (+)MAPPERmRatBN7.2
Rnor_6.01237,909,274 - 237,909,433NCBIRnor6.0
Rnor_5.01245,208,166 - 245,208,325UniSTSRnor5.0
RGSC_v3.41223,493,727 - 223,493,886UniSTSRGSC3.4
Celera1215,154,241 - 215,154,400UniSTS
Cytogenetic Map1q51UniSTS
D1Bda58  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21217,861,237 - 217,861,491 (+)MAPPERmRatBN7.2
Rnor_6.01237,894,046 - 237,894,299NCBIRnor6.0
Rnor_5.01245,192,938 - 245,193,191UniSTSRnor5.0
RGSC_v3.41223,478,499 - 223,478,752UniSTSRGSC3.4
Celera1215,139,013 - 215,139,266UniSTS
Cytogenetic Map1q51UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High 1
Medium 3 43 42 26 19 26 8 10 9 35 31 11 8
Low 15 15 15 1 65 9
Below cutoff

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000023664   ⟹   ENSRNOP00000023664
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1217,861,175 - 217,877,202 (-)Ensembl
Rnor_6.0 Ensembl1237,893,966 - 237,910,012 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000094974   ⟹   ENSRNOP00000085643
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1217,861,175 - 217,877,209 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000096060   ⟹   ENSRNOP00000090466
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1217,861,189 - 217,877,210 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000096367   ⟹   ENSRNOP00000087822
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1217,861,279 - 217,877,195 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000109210   ⟹   ENSRNOP00000093263
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1217,861,183 - 217,877,343 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000116454   ⟹   ENSRNOP00000078049
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1217,861,178 - 217,877,209 (-)Ensembl
RefSeq Acc Id: NM_012904   ⟹   NP_037036
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81227,287,713 - 227,303,732 (-)NCBI
mRatBN7.21217,861,175 - 217,877,194 (-)NCBI
Rnor_6.01237,893,983 - 237,910,002 (-)NCBI
Rnor_5.01245,192,875 - 245,220,057 (-)NCBI
RGSC_v3.41223,478,436 - 223,494,455 (-)RGD
Celera1215,138,950 - 215,154,969 (-)RGD
Sequence:
RefSeq Acc Id: XM_039101605   ⟹   XP_038957533
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81227,287,713 - 227,303,743 (-)NCBI
mRatBN7.21217,861,175 - 217,877,205 (-)NCBI
RefSeq Acc Id: XM_063281726   ⟹   XP_063137796
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81227,287,713 - 227,306,739 (-)NCBI
Reference Protein Sequences
RefSeq Acc Id: NP_037036   ⟸   NM_012904
- UniProtKB: Q64664 (UniProtKB/Swiss-Prot),   P07150 (UniProtKB/Swiss-Prot),   A6I0K9 (UniProtKB/TrEMBL),   A0A8I6GKK9 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000023664   ⟸   ENSRNOT00000023664
RefSeq Acc Id: XP_038957533   ⟸   XM_039101605
- Peptide Label: isoform X1
- UniProtKB: P07150 (UniProtKB/Swiss-Prot),   Q64664 (UniProtKB/Swiss-Prot),   A6I0K9 (UniProtKB/TrEMBL),   A0A8I6GKK9 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000085643   ⟸   ENSRNOT00000094974
RefSeq Acc Id: ENSRNOP00000093263   ⟸   ENSRNOT00000109210
RefSeq Acc Id: ENSRNOP00000087822   ⟸   ENSRNOT00000096367
RefSeq Acc Id: ENSRNOP00000090466   ⟸   ENSRNOT00000096060
RefSeq Acc Id: ENSRNOP00000078049   ⟸   ENSRNOT00000116454
RefSeq Acc Id: XP_063137796   ⟸   XM_063281726
- Peptide Label: isoform X1
- UniProtKB: Q64664 (UniProtKB/Swiss-Prot),   P07150 (UniProtKB/Swiss-Prot),   A6I0K9 (UniProtKB/TrEMBL)

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P07150-F1-model_v2 AlphaFold P07150 1-346 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13690811
Promoter ID:EPDNEW_R1336
Type:multiple initiation site
Name:Anxa1_1
Description:annexin A1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01237,910,017 - 237,910,077EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2118 AgrOrtholog
BioCyc Gene G2FUF-56180 BioCyc
Ensembl Genes ENSRNOG00000017469 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOG00055010464 UniProtKB/Swiss-Prot
  ENSRNOG00060023625 UniProtKB/Swiss-Prot
  ENSRNOG00065026926 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000023664.7 UniProtKB/TrEMBL
  ENSRNOT00000094974.1 UniProtKB/TrEMBL
  ENSRNOT00000096060 ENTREZGENE
  ENSRNOT00000096060.1 UniProtKB/Swiss-Prot
  ENSRNOT00000096367.1 UniProtKB/TrEMBL
  ENSRNOT00000109210.1 UniProtKB/TrEMBL
  ENSRNOT00000116454 ENTREZGENE
  ENSRNOT00000116454.1 UniProtKB/TrEMBL
  ENSRNOT00055017732 UniProtKB/Swiss-Prot
  ENSRNOT00060041157 UniProtKB/Swiss-Prot
  ENSRNOT00065046509 UniProtKB/Swiss-Prot
Gene3D-CATH 1.10.220.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:5598112 IMAGE-MGC_LOAD
InterPro Annexin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Annexin_repeat UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Annexin_repeat_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Annexin_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ANX1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25380 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
MGC_CLONE MGC:72548 IMAGE-MGC_LOAD
NCBI Gene 25380 ENTREZGENE
PANTHER ANNEXIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR10502:SF17 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Annexin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Anxa1 PhenoGen
PRINTS ANNEXIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ANNEXINI UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE ANNEXIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ANNEXIN_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000017469 RatGTEx
  ENSRNOG00055010464 RatGTEx
  ENSRNOG00060023625 RatGTEx
  ENSRNOG00065026926 RatGTEx
SMART ANX UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF47874 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A8I5ZKF7_RAT UniProtKB/TrEMBL
  A0A8I6A8I9_RAT UniProtKB/TrEMBL
  A0A8I6GD51_RAT UniProtKB/TrEMBL
  A0A8I6GKK9 ENTREZGENE, UniProtKB/TrEMBL
  A0A8L2UJV2_RAT UniProtKB/TrEMBL
  A6I0K9 ENTREZGENE, UniProtKB/TrEMBL
  ANXA1_RAT UniProtKB/Swiss-Prot, ENTREZGENE
  Q64664 ENTREZGENE
UniProt Secondary Q64664 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-09-10 Anxa1  annexin A1    annexin 1  Name updated 1299863 APPROVED
2002-11-06 Anxa1  annexin 1  Anx1  Annexin 1 (p35) (Lipocortin 1)  Symbol and Name updated 625702 APPROVED
2002-06-10 Anx1  Annexin 1 (p35) (Lipocortin 1)      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_cellular_localization localizes in insulin-containing vesicles 628365
gene_domains contain several putative calcium binding domains 632207
gene_expression expressed in blood cells, fibroblast-like synoviocytes, adrenal chromaffin cells, anterior pituitary cells, and pancreatic-beta cells 628365
gene_pathway insulin secretion 628365
gene_process plays a role in the regulation of glucose-induced insulin secretion via the protein phosphorylation process and is involoved in exocytosis, membrane trafficking, endocytosis, and anti-inflammation 628365
gene_process may inhibit phospholipase A2 632207
gene_process may play a role in regulation of inflammatory response 632208
gene_process mediates insulin release in pancreatic islets and is independent of extracellular Ca2+ 628365
gene_product member of the annexin superfamily; 37 kDa 628365
gene_product member of a family of calcium dependent phospholipid binding proteins that inhibit phospholipase A2 632207